Khaitan & Co  and Cyril Amarchand Mangaldas are advising Indian drugmaker Gland Pharma on its planned $780 million IPO, with Herbert Smith Freehills and S&R Associates acting for the bookrunners and lead managers.

The Hyderabad-headquartered Gland Pharma, a subsidiary of China’s Fosun Pharmaceutical, is a major supplier of API heparin to hospitals in India. Its IPO will make it the first Indian company with a Chinese parent to list its equity shares on an Indian stock exchange.

The bookrunning lead managers are Kotak Mahindra Capital, Citigroup Global Markets India, Haitong Securities India and Nomura India.

The Khaitan team is being led by partners Abhimanyu Bhattacharya, Aditya Cheriyan, Niren Patel and Vivek Sriram.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Appointments

Khaitan expands new Ahmedabad office with disputes hire

by Mari Iwata |

Khaitan & Co, India’s largest law firm by headcount, has welcomed aboard disputes expert Digant Popat as a partner in its recently launched Ahmedabad office.

Deals

AZB, Khaitan, SAM guide Sterlite-GIC $1 bln power JV

by Nimitt Dixit |

Indian law firms AZB & Partners and Khaitan & Co have advised energy company Sterlite Power and Shardul Amarchand Mangaldas has represented Singapore sovereign wealth fund GIC on the creation of their joint venture to build a power transmission platform in India.

Features

FORUM: Listen to the Client

by Nimitt Dixit |

A Thomson Reuters Market Insights research report has revealed that law firms conducting formal client feedback programs can earn nearly twice the share of a client’s external legal spend compared to those not engaging in feedback. Client feedback plays a pivotal role in helping law firms evaluate their performance, improve service quality, build strong client relationships, and differentiate themselves in a competitive Indian legal market.